DK3609535T3 - Hbv-vaccine - Google Patents
Hbv-vaccineInfo
- Publication number
- DK3609535T3 DK3609535T3 DK18719248.9T DK18719248T DK3609535T3 DK 3609535 T3 DK3609535 T3 DK 3609535T3 DK 18719248 T DK18719248 T DK 18719248T DK 3609535 T3 DK3609535 T3 DK 3609535T3
- Authority
- DK
- Denmark
- Prior art keywords
- hbv vaccine
- hbv
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
- C12Y301/26004—Ribonuclease H (3.1.26.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1705765.4A GB201705765D0 (en) | 2017-04-10 | 2017-04-10 | HBV vaccine |
| PCT/GB2018/050948 WO2018189522A1 (en) | 2017-04-10 | 2018-04-10 | Hbv vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3609535T3 true DK3609535T3 (da) | 2025-08-18 |
Family
ID=58744773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18719248.9T DK3609535T3 (da) | 2017-04-10 | 2018-04-10 | Hbv-vaccine |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200113998A1 (da) |
| EP (1) | EP3609535B1 (da) |
| JP (1) | JP7326157B2 (da) |
| KR (1) | KR102700586B1 (da) |
| CN (2) | CN110913899B (da) |
| AU (1) | AU2018251241B2 (da) |
| CA (1) | CA3059290A1 (da) |
| DK (1) | DK3609535T3 (da) |
| ES (1) | ES3036962T3 (da) |
| GB (1) | GB201705765D0 (da) |
| MX (1) | MX2019012101A (da) |
| MY (1) | MY202396A (da) |
| PH (1) | PH12019502310A1 (da) |
| SG (1) | SG11201909353VA (da) |
| WO (1) | WO2018189522A1 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| CN113573730A (zh) * | 2019-03-05 | 2021-10-29 | 葛兰素史密斯克莱生物公司 | 乙型肝炎免疫方案和组合物 |
| WO2020255008A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
| TWI828168B (zh) * | 2019-06-20 | 2024-01-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途 |
| MX2022002270A (es) * | 2019-08-29 | 2022-03-22 | Vir Biotechnology Inc | Vacunas contra el virus de la hepatitis b. |
| EP4458975A3 (en) * | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| WO2021243149A2 (en) * | 2020-05-28 | 2021-12-02 | President And Fellows Of Harvard College | Protein covariance networks reveal interactions important to the emergence of sars coronaviruses as human pathogens |
| CA3188801A1 (en) * | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
| JPWO2022071513A1 (da) | 2020-10-02 | 2022-04-07 | ||
| WO2022133230A1 (en) * | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| CN115595312A (zh) * | 2021-06-28 | 2023-01-13 | 中国农业大学（Cn） | 一种重组腺病毒及其应用 |
| US20250000968A1 (en) * | 2021-11-12 | 2025-01-02 | The United States of America, as represented by the Secretary,Department of Health and Human Service | Sars-cov-2 spike fused to a hepatitis b surface antigen |
| EP4444347A1 (en) | 2021-12-07 | 2024-10-16 | Barinthus Biotherapeutics (UK) Limited | Vaccine boost methods and compositions |
| AU2024241503A1 (en) * | 2023-03-17 | 2025-08-14 | Albert-Ludwigs-Universität Freiburg | Hbv antigen formulation for treating hepatitis b |
| GB202317925D0 (en) | 2023-11-23 | 2024-01-10 | Spybiotech Ltd | Vaccines |
| CN118593695B (zh) * | 2024-08-07 | 2024-10-22 | 山东兴瑞生物科技有限公司 | 一种用于治疗HBV感染的siRNA和mRNA联合疫苗 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5679394A (en) | 1992-11-25 | 1994-06-22 | International Biotechnology Laboratories, Inc. | Hepatitis b virus vaccines |
| CA2526120A1 (en) * | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| CN101573449B (zh) * | 2006-08-14 | 2013-09-18 | 浦项工大产学协力团 | 用于治疗慢性乙型肝炎的dna疫苗及其制备方法 |
| US10076570B2 (en) | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
| BR112012002628B1 (pt) * | 2009-08-07 | 2021-09-08 | Transgene Sa | Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes |
| JP5745102B2 (ja) * | 2011-02-12 | 2015-07-08 | グローブイミューン，インコーポレイテッド | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 |
| TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| CN103173492B (zh) * | 2013-03-12 | 2014-08-13 | 中国人民解放军白求恩国际和平医院 | 携带外源基因的复制型hbv载体、其转染后产生的重组hbv，和相应的制备方法与应用 |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
-
2017
- 2017-04-10 GB GBGB1705765.4A patent/GB201705765D0/en not_active Ceased
-
2018
- 2018-04-10 US US16/604,221 patent/US20200113998A1/en not_active Abandoned
- 2018-04-10 EP EP18719248.9A patent/EP3609535B1/en active Active
- 2018-04-10 DK DK18719248.9T patent/DK3609535T3/da active
- 2018-04-10 CA CA3059290A patent/CA3059290A1/en active Pending
- 2018-04-10 CN CN201880028408.6A patent/CN110913899B/zh active Active
- 2018-04-10 SG SG11201909353V patent/SG11201909353VA/en unknown
- 2018-04-10 KR KR1020197031896A patent/KR102700586B1/ko active Active
- 2018-04-10 WO PCT/GB2018/050948 patent/WO2018189522A1/en not_active Ceased
- 2018-04-10 CN CN202410387306.0A patent/CN118576699A/zh active Pending
- 2018-04-10 AU AU2018251241A patent/AU2018251241B2/en active Active
- 2018-04-10 MX MX2019012101A patent/MX2019012101A/es unknown
- 2018-04-10 MY MYPI2019005911A patent/MY202396A/en unknown
- 2018-04-10 ES ES18719248T patent/ES3036962T3/es active Active
- 2018-04-10 JP JP2019555196A patent/JP7326157B2/ja active Active
-
2019
- 2019-10-08 PH PH12019502310A patent/PH12019502310A1/en unknown
-
2023
- 2023-06-06 US US18/206,249 patent/US12521431B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN118576699A (zh) | 2024-09-03 |
| JP2020516264A (ja) | 2020-06-11 |
| US20240115694A1 (en) | 2024-04-11 |
| AU2018251241A1 (en) | 2019-10-31 |
| US20200113998A1 (en) | 2020-04-16 |
| CN110913899B (zh) | 2024-04-19 |
| SG11201909353VA (en) | 2019-11-28 |
| WO2018189522A1 (en) | 2018-10-18 |
| MY202396A (en) | 2024-04-25 |
| EP3609535B1 (en) | 2025-06-25 |
| JP7326157B2 (ja) | 2023-08-15 |
| MX2019012101A (es) | 2019-12-11 |
| US12521431B2 (en) | 2026-01-13 |
| KR102700586B1 (ko) | 2024-08-30 |
| CN110913899A (zh) | 2020-03-24 |
| KR20200024130A (ko) | 2020-03-06 |
| AU2018251241B2 (en) | 2025-04-17 |
| PH12019502310A1 (en) | 2020-09-21 |
| GB201705765D0 (en) | 2017-05-24 |
| ES3036962T3 (en) | 2025-09-25 |
| CA3059290A1 (en) | 2018-10-18 |
| EP3609535A1 (en) | 2020-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3538146A4 (en) | INFLUENZA VACCINE | |
| DK3393510T3 (da) | Zikavirusvaccine | |
| IL259077A (en) | Vaccines against hepatitis b virus | |
| EP3522831C0 (en) | NEO-PHALLUS IMPLANT | |
| DK3400291T3 (da) | Manipuleret virus | |
| EP3505033A4 (en) | VACUUM | |
| DK3565568T3 (da) | Ændret virus | |
| GB201705765D0 (en) | HBV vaccine | |
| EP3406172A4 (en) | VACUUM CLEANER | |
| EP3424390A4 (en) | VACUUM CLEANER | |
| EP3424387A4 (en) | VACUUM CLEANER | |
| EP3424394A4 (en) | VACUUM CLEANER | |
| FI20155008A7 (fi) | Ajoneuvoavusteinen työlaite | |
| EP3485779A4 (en) | VACUUM | |
| EP3440972A4 (en) | VACUUM CLEANER | |
| EP3563741A4 (en) | VACUUM CLEANER | |
| EP3560512A4 (en) | COMPOSITION OF VACCINE AGAINST ZONA | |
| EP3424391A4 (en) | VACUUM CLEANER | |
| EP3402423C0 (fr) | Dispositif d'implant | |
| DK3129007T3 (da) | Vaccinesammensætninger | |
| EP3488748A4 (en) | VACUUM CLEANER | |
| EP3485774A4 (en) | VACUUM | |
| EP3424392A4 (en) | VACUUM CLEANER | |
| EP3424393A4 (en) | VACUUM CLEANER | |
| EP3638297A4 (en) | BACTERIAL VACCINE |